Treating fibrosis using a TGFβ neutralizing antibody in the STAMTM mouse model fibrosis-associated HCC, triggered a redistribution of CD8+ lymphocytes into the tumors, which re-invigorated anti-tumor response (95). This evidence concerns the gene CD8A and neoplasm.